Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for chemotherapy-induced peripheral neuropathy
NCT00489411Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2008
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of duloxetine in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Brief Pain Inventory-Short Form Average Pain Severity at 5 weeks. Started Apr 2008; status: completed.
02
Drugs
duloxetine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00489411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00489411.